Bepotastine

Bepotastine
Clinical data
Trade names	Bepreve
AHFS/Drugs.com	International Drug Names
MedlinePlus	a610012
Routes of; administration	Oral, eye drops
ATC code	none;
Legal status
Legal status	CA: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	High (oral); Minimal (topical)
Protein binding	~55%
Excretion	Renal (75–85
Identifiers
	IUPAC name 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid;
CAS Number	125602-71-3 ;
PubChem CID	2350;
DrugBank	DB04890 ;
ChemSpider	2260 ;
UNII	HYD2U48IAS;
KEGG	D09705 ;
ChEBI	CHEBI:71204 ;
ChEMBL	ChEMBL1201758 ;
CompTox Dashboard (EPA)	DTXSID90904947 ;
Chemical and physical data
Formula	C21H25ClN2O3
Molar mass	388.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1ccc(cc1)C(OC2CCN(CCCC(=O)O)CC2)c3ncccc3;
	InChI InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26) ; Key:YWGDOWXRIALTES-UHFFFAOYSA-N ;
	(what is this?) (verify)

Bepotastine (Talion, Bepreve) is a 2nd generation antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000, and January 2002, respectively. It is marketed in the United States as an eye drop under the brand name Bepreve, by ISTA Pharmaceuticals, a subsidiary of Bausch + Lomb.